VALUE is 20 years old14; in current times patients also take other ARBs,56,57 statins,58,59 finerenone,60,61 sodium-glucose-cotransporter-2 inhibitors,62–64 or glucagon-like peptide-1-receptor agonists,65 which can improve cardiovascular and kidney outcomes of patients with DM and/or kidney disease. This evidence concerns the gene SLC5A2 and kidney disorder.